Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01263379
Other study ID # SU-10202010-7130
Secondary ID R01AR055914RAC P
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date October 5, 2010
Est. completion date March 9, 2022

Study information

Verified date August 2023
Source Abeona Therapeutics, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial will create a skin graft, which the investigators call "LEAES," using the patient's own skin cells that have been genetically engineered in the lab to express a missing protein called type VII collagen. The corrected cells will be transplanted back to the patient.


Description:

The research project involves gene transfer into keratinocytes, which are the majority of the cells in the outer layer of skin. In this gene transfer trial we plan to biopsy some skin tissue, grow the cells in a skin cell culture (sterile dishes with special fluid that allows cells to grow and multiply) and then infect the cells with a virus that we have genetically engineered to insert the correct type VII collagen gene. The cells should then make type VII collagen. The process of inserting the correct type VII collagen gene into cells is called "gene transfer." The virus used is called a "retrovirus." The virus is made so that it only delivers the type VII collagen gene and it should not spread to other parts of the body. During the study we will check for growth of the virus. After cells have received gene transfer, we will grow the cells in culture into a sheet of cells that look like a plastic film. We plan to graft the sheet to wounds. Grafting means we will take cells from the culture and stitch them to the patient's skin.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date March 9, 2022
Est. primary completion date March 9, 2022
Accepts healthy volunteers No
Gender All
Age group 13 Years and older
Eligibility Inclusion Criteria: 1. Clinical diagnosis of recessive dystrophic epidermolysis bullosa (RDEB) 2. 13 years old or older and willing and able to give assent/consent 3. Confirmation of RDEB diagnosis by immunofluorescence (IF) and electron microscopy (EM) 4. NC1[+] and mAb LH24 antibody staining negative 5. RDEB type VII collagen mutations in subject and carrier parents confirmed 6. At least 100 to 200 cm2 areas of open erosions on the trunk and/or extremities suitable for skin grafting 7. Able to undergo adequate anesthesia to allow grafting procedures to take place. Exclusion Criteria: 1. Medical instability limiting ability to travel to Stanford University Medical Center 2. The presence of medical illness expected to complicate participation and/or compromise the safety of this technique, such as active infection with HIV, hepatitis B or hepatitis C, as determined by hepatitis B surface antigen screening, detection of hepatitis C antibodies, or positive result of hepatitis C polymerase chain reaction (PCR) analysis. 3. Antibodies to type VII collagen associated antigens 4. Active infection in the area that will undergo grafting 5. Evidence of systemic infection 6. Current evidence or a history of squamous cell carcinoma in the area that will undergo grafting 7. Active drug or alcohol addiction 8. Hypersensitivity to vancomycin or amikacin 9. Receipt of chemical or biological study product for the specific treatment of RDEB in the past six months 10. Positive pregnancy test or breast-feeding 11. Clinically significant abnormalities (Grade 2 or higher on the National Cancer Institute [NCI] toxicity scale) on laboratory tests performed prior to grafting, except for the following specific exclusionary laboratory threshold results, subject to approval or exemption by the EB physician: - Albumin < 2.5 g/dL - Leukocytes > 20K/uL - Hemoglobin < 7.5 g/dL. Low hemoglobin will be treated at the discretion of the investigators and the EB physician. - Additional exceptions may be made at the discretion of the investigators and the EB physician. 12. Clinically significant abnormalities (Grade 2 or higher on the NCI toxicity scale) identified through medical history and physical examination on Day 0, with the following exceptions: - Anorexia, can enroll up to Grade 4 (inclusive) - Constipation, can enroll up to Grade 2 (inclusive) - Dysphagia, can enroll up to Grade 4 (inclusive) - Keratitis, can enroll up to Grade 4 (inclusive) - Bone pain, can enroll up to Grade 2 (inclusive) - Additional exceptions may be made at the discretion of the investigators and the EB physician.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
This trial will create a graft, which we call "LEAES", of the patient's own skin that has been genetically engineered in our lab to express this missing protein.

Locations

Country Name City State
United States Stanford University, School of Medicine, Dept of Dermatology Redwood City California

Sponsors (3)

Lead Sponsor Collaborator
Abeona Therapeutics, Inc National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of Participants With Presence of Anchoring Fibrils (AF) Skin biopsies were obtained to observe physical development of the anchoring fibrils using electron microscopy 3 months, 6 months, 12 months and 24 months post grafting
Primary Number of Wounds by Healing Category Per Investigator Visual Assessment The graft site was clinically evaluated by the investigator with a global score of: 1) 100% to 75% healed, 2) 74% to 50% healed, 3) 49% or less healed with 100% meaning completely healed. 3, 6, 12 and 24 months post grafting
Primary Percentage Surface Area of Wound Healing Percentage of wound area will be obtained using the Canfield system. Changes in dimensions between visits as well as changes in dimensions from baseline will be recorded. Dimensions of untreated wounded skin will be used for comparison 3, 6 and 12 months post grafting
Secondary Number Participants Positive for NC2 Epitope as a Measure of Duration of Type VII Collagen Production Skin biopsies were obtained to evaluate expression of type VII collagen, NC2 epitope, using immuno-electron microscopy and immuno-fluorescent light microscopy. 3 months, 6 months, 12 months, 24 months post-grafting
See also
  Status Clinical Trial Phase
Completed NCT00380640 - The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa Phase 2
Completed NCT00004761 - Establishment of the National Epidermolysis Bullosa Registry N/A
Completed NCT01716169 - Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care N/A
Withdrawn NCT01454687 - Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes N/A
Completed NCT00014729 - Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa Phase 1
Recruiting NCT05838092 - Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III) Phase 3
Recruiting NCT03269474 - Computational Drug Repurposing for All EBS Cases
Completed NCT03068780 - Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa Phase 3
Terminated NCT02090283 - Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa Phase 2
Completed NCT02582775 - MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs Phase 2
Recruiting NCT04213703 - A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
Completed NCT02384460 - ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa Phase 3
Terminated NCT02670330 - Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa Phase 3
Terminated NCT01619670 - A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa Phase 4
Recruiting NCT01340235 - Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin Phase 3
Completed NCT02014376 - Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa Phase 2
Completed NCT04217538 - Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa
Completed NCT03942250 - Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients N/A
Completed NCT01033552 - Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs Phase 1/Phase 2
Completed NCT04227106 - Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) Phase 3